Venus Concept Inc.: insider trades · United States · SEC (Form 4)

About Venus Concept Inc.

Venus Concept Inc. is a U.S.-listed medical technology company trading on the NASDAQ under the ticker VERO. While its principal executive offices are in Toronto, Ontario, the issuer is a Delaware corporation in the United States, and its commercial footprint is global. The company was founded on November 22, 2002 and has built its business around minimally invasive and non-invasive medical aesthetic technologies, together with hair restoration solutions and related services. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1409269/000143774925009968/vero20241231_10k.htm)) At the core of Venus Concept’s model is a portfolio of medical devices and adjacent services sold to physicians, dermatologists, plastic surgeons and aesthetic practices. Historically, the company has focused on energy-based aesthetic platforms and robotic hair restoration systems, supported by training, clinical education and practice-growth services. One of its best-known technologies is the ARTAS system, a robotic platform designed to assist physicians in key steps of hair restoration procedures, including follicle harvesting and site making. In addition, the company offers structured financing and commercial programs, notably Venus Prime, which replaced its legacy North America subscription model and provides customers with payment flexibility and a technology upgrade path. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1409269/000143774925009968/vero20241231_10k.htm)) From a competitive standpoint, Venus Concept operates in a specialized but crowded segment that sits at the intersection of aesthetic medicine, capital equipment, recurring financing and practice support. Its differentiator is an integrated offering that combines devices, consumables, software-enabled workflows, internal financing and business-development support. Management disclosed that as of December 31, 2024 the company operated directly in 12 international markets, with offices in the United States, Canada, Japan, Mexico, Spain, Germany, Australia, China, Hong Kong and Israel. That geographic reach gives the business a meaningful international profile, even though North America remains strategically important. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1409269/000114036125016519/ny20045858x2_ars.pdf?utm_source=openai)) Recent developments have been important for investors. In June 2025, Venus Concept announced a definitive agreement to sell its Venus Hair business for $20 million, a move intended to strengthen the balance sheet and fund strategic growth initiatives. In July 2025, the company also announced a $6.5 million debt-to-equity exchange transaction, further reducing outstanding debt. Most notably, in November 2025, Venus Concept received FDA 510(k) clearance for Venus NOVA, described as a next-generation multi-application platform for non-invasive body and skin treatments. Taken together, these actions suggest a company still in turnaround mode, balancing restructuring, deleveraging and product innovation. ([ir.venusconcept.com](https://ir.venusconcept.com/news-releases/news-release-details/venus-concept-announces-definitive-agreement-sell-venus-hair/?utm_source=openai))